---
layout: default
title: Pembrolizumab
parent: 僅模型預測 (L5)
nav_order: 484
evidence_level: L5
indication_count: 10
---

# Pembrolizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Pembrolizumab: From Oncology Indications to Fibromatosis, Gingival

## One-Sentence Summary

> Pembrolizumab is a PD-1 immune checkpoint inhibitor used in oncology; the specific original approved indication is not recorded in this evidence pack (data gap).
> The TxGNN model predicts it may be effective for **Fibromatosis, Gingival**,
> but currently **0 clinical trials** and **0 publications** support this specific pairing, and the model's own mechanistic rationale finds no plausible biological link.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in this evidence pack (drug class context indicates oncology / PD-1 immune checkpoint inhibitor) |
| Predicted New Indication | Fibromatosis, gingival |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data is not formally available in this evidence pack (data gap). Based on the supporting rationale text that accompanies this candidate, pembrolizumab is a PD-1 immune checkpoint inhibitor that acts on T-cell exhaustion within the tumor microenvironment, restoring anti-tumor T-cell activity — a mechanism broadly applied across immuno-oncology indications.

Gingival fibromatosis, however, is a benign connective-tissue overgrowth condition (typically hereditary or drug-induced by agents such as phenytoin, cyclosporine, or calcium channel blockers). It is not driven by tumor-associated immune evasion, and there is no known intersection with the PD-1/PD-L1 axis.

Based on the evidence pack's own assessment, this prediction is **not mechanistically supported**: the pipeline's rationale explicitly states "無合理機轉關聯" (no reasonable mechanistic link) between pembrolizumab's checkpoint-inhibition activity and gingival fibromatosis pathophysiology. This is a case where a high TxGNN embedding-similarity score does not correspond to biological plausibility.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Saudi Arabia Market Information

Pembrolizumab is currently not marketed in the tracked jurisdiction, and no authorization records are available in this evidence pack (0 licenses).

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Immunotherapy (PD-1 immune checkpoint inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN score (99.40%) reflects embedding-space proximity rather than validated efficacy — there are zero clinical trials and zero publications for this specific drug-disease pairing, and the pack's own mechanistic rationale confirms no biologically plausible link between PD-1 blockade and gingival fibromatosis, a benign, non-immune-driven condition.

**To proceed, the following is needed:**
- Confirmed original indication and regulatory approval history for pembrolizumab (currently a data gap)
- Formal MOA documentation from DrugBank
- Local package insert warnings, contraindications, and DDI data
- If pursuing repurposing research on this drug further, note that within the same evidence pack, **lung hilum carcinoma** (rank 4, L3 evidence, Research Question) and **lung germ cell tumor** (rank 9, L4 evidence, Research Question) carry partial trial/literature support and are better candidates for follow-up — though both still require manual verification of disease-entity matching due to noted ontology mismatches in the retrieved evidence.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

